Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC).: A phase II study of the Galician Lung Cancer Group

被引：0

作者：

Vazquez-Estevez, S. ^{[1
]}

Firvida, J. L. ^{[2
]}

Grande, C. ^{[3
]}

Baron, F. ^{[4
]}

Lazaro, M. ^{[5
]}

Salgado, M. ^{[2
]}

Campos, B. ^{[1
]}

Casal, J. ^{[3
]}

Perez, E. ^{[2
]}

Mel, J. R. ^{[1
]}

机构：

[1] Complexo Hosp Xeral Calde, Lugo, Spain

[2] Complexo Hosp Ourense, Orense, Spain

[3] Hosp Meixoeiro, Vigo, Spain

[4] Complexo Hosp Univ Santiago, Santiago De Compostela, Spain

[5] Complexo Hosp Xeral Cies, Vigo, Spain

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)71443-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6615

引用

页码：392 / 392

页数：1

共 50 条

[31] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
Das, Devika
Robert, Francisco
Bordoni, Rodolfo
Grant, Stefan C.
Saleh, Mansoor N.
Reddy, Vishnu
Jerome, Mary
Miley, Debi
Singh, Karen P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer as Frontline and Second-Line Therapy
William, William N., Jr.
Khuri, Fadlo R.
Fossella, Frank V.
Glisson, Bonnie S.
Zinner, Ralph G.
Lee, J. Jack
Herbst, Roy S.
Lippman, Scott M.
Kim, Edward S.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 148 - 152
[33] A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer
Cho, KH
Song, YB
Choi, IS
Cho, EH
Choi, JW
Ahn, YM
Roh, YH
Nam, SH
Kim, BS
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (01) : 50 - 54
[34] A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer
Yoshitaka Totani
Yuji Saito
Masamichi Hayashi
Toshihiko Tada
Yasuo Kohashi
Yuki Mieno
Atsushi Kato
Hiromi Imizu
Yukiko Yoneda
Tami Hoshino
Yasuhiro Uchiyama
Yasuo Takeuchi
Mitsushi Okazawa
Hiroki Sakakibara
Cancer Chemotherapy and Pharmacology, 2009, 64
[35] A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer
Totani, Yoshitaka
Saito, Yuji
Hayashi, Masamichi
Tada, Toshihiko
Kohashi, Yasuo
Mieno, Yuki
Kato, Atsushi
Imizu, Hiromi
Yoneda, Yukiko
Hoshino, Tami
Uchiyama, Yasuhiro
Takeuchi, Yasuo
Okazawa, Mitsushi
Sakakibara, Hiroki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1181 - 1185
[36] A phase II study by the Norwegian lung cancer group: Pemetrexed as second-line chemotherapy in recurrent small-cell lung cancer
Gronberg, Bjorn H.
Sundstrom, Stein
Bremnes, Roy
Aasebo, Ulf
Brunsvig, Paal
von Plessen, Christian
Wang, Mari
Flotten, Oystein
ANNALS OF ONCOLOGY, 2006, 17 : 233 - 233
[37] Concomitant ChemoRadiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study from the Galician Lung Cancer Group
Gomez, Susana
Areses, Carmen
Fernandez, Natalia
Garcia, Jorge
Costa, Marinha
Firvida, Jose Luis
Campos, Begona
Hernandez, Elena
Taboada, Begona
Castro, Enrique
Veiras, Maria
Afonso, Javier
Azpitarte, Cristina
Amenedo, Margarita
Casal Rubio, Joaquin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S864 - S865
[38] Phase II study of celecoxib and weekly paclitaxel in the treatment of pretreated advanced non-small cell lung cancer (NSCLC).
Stani, SC
Carillio, G
Meo, S
Morabito, A
Bonginelli, P
Comella, G
Mansueto, G
Avallone, A
Gion, M
Gasparini, G
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 700S - 700S
[39] Second-line treatment of small cell lung cancer
Schmittel, A.
Sebastian, M.
Niederle, N.
ONKOLOGE, 2013, 19 (11): : 940 - +
[40] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
Kayali, F.
Janjua, M. A.
Laber, D. A.
Miller, D. M.
Day, J. M.
Kloecker, G. H.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →